TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18646005

Group type: EXPERIMENTAL
Intervention: interesterified butter blend with fish oil (352 mg n‐3 long‐chain PUFA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: commercial butter blend
Number of subjects: 12
Study: 16269449

Group type: EXPERIMENTAL
Intervention: OCP group (n = 214)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Non-OCP group (n = 211)
Number of subjects: 425
Study: 12652607

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral relaxation training groups (CBSM)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Social support groups (SSG)
Number of subjects: 148

Group type: COMPARATOR
Intervention: WAIT‐listed control group
Number of subjects: 148
Study: 10949982

Group type: EXPERIMENTAL
Intervention: Teicoplanin (10 mg x kg(‐1) x d(‐1))
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vancomycin (40 mg x kg(‐1) x d(‐1)) plus ceftazidime and netilmicin
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 32

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 32
Study: 1684749

Group type: EXPERIMENTAL
Intervention: Methyldopa (500 mg to 1 g daily)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Rilmenidine (1 to 2 mg daily)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 157

Group type: COMPARATOR
Intervention: Rilmenidine
Number of subjects: 157
Study: 6753223

Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (exercise training after control period)
Number of subjects: 34
Study: 29578271

Group type: EXPERIMENTAL
Intervention: Psychoeducation (8 sessions of group-based psychoeducation)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Regular free discussions (control group)
Number of subjects: 100
Study: 29390001

Group type: EXPERIMENTAL
Intervention: Dynamic open kinetic chain stretching (DS)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dynamic closed kinetic chain stretching (LEC)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Jogging only (CON)
Number of subjects: 36
Study: 27135066

Group type: EXPERIMENTAL
Intervention: Capsinoids
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24646429

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI) for medication-overuse headache (MOH)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Feedback from GPs and patients about the feasibility and logistics of the study design, screening/recruitment process, BI and headache interviews
Number of subjects: 6
Study: 22915657

Group type: EXPERIMENTAL
Intervention: palonosetron + dexamethasone on day 1 with prochlorperazine on days 2 and 3
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: aprepitant + palonosetron + dexamethasone on day 1 with aprepitant + dexamethasone on days 2 and 3
Number of subjects: 234

Group type: COMPARATOR
Intervention: granisetron + dexamethasone on day 1 with prochlorperazine on days 2 and 3
Number of subjects: 234
Study: 20156957

Group type: EXPERIMENTAL
Intervention: Brief Strategic Family Therapy (BSFT)
Number of subjects: 1819

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 1819

Group type: EXPERIMENTAL
Intervention: Adolescents (BSFT and TAU combined)
Number of subjects: 1819

Group type: EXPERIMENTAL
Intervention: Family members (BSFT)
Number of subjects: 1819
Study: 17265549

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (manual needle stimulation of 19 acupoints, 30 min sessions, 10 sessions over a year)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy controls (20 non-anxious women)
Number of subjects: 34
Study: 16105122

Group type: EXPERIMENTAL
Intervention: 30 mg lansoprazole initially and maintenance therapy with a standard dose H(2)‐RA
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 30 mg of lansoprazole initially and maintenance therapy of 15 mg lansoprazole
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: 15 mg of lansoprazole once daily for 16 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Stepped down to famotidine
Number of subjects: 43
Study: 12688626

Group type: EXPERIMENTAL
Intervention: Mite-impermeable mattress and pillow covers
Number of subjects: 4146

Group type: COMPARATOR
Intervention: Natural history study (no specific intervention mentioned)
Number of subjects: 4146

Group type: EXPERIMENTAL
Intervention: Intervention measure
Number of subjects: 4146
Study: 10395849

Group type: EXPERIMENTAL
Intervention: Stavudine plus didanosine (group 1)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Zidovudine plus lamivudine (group 2)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Stavudine plus didanosine followed by zidovudine plus lamivudine (group 3)
Number of subjects: 151
Study: 7569759

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 89

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study: 2309835

Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 10
Study: 6644887

Group type: EXPERIMENTAL
Intervention: Doxorubicin with urokinase
Number of subjects: 44

Group type: COMPARATOR
Intervention: Doxorubicin without urokinase
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Doxorubicin with or without urokinase
Number of subjects: 44
Study: 30478608

Group type: EXPERIMENTAL
Intervention: Procedural WM training
Number of subjects: 175

Group type: COMPARATOR
Intervention: Active-control training
Number of subjects: 175

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 175
Study: 30499443

Group type: EXPERIMENTAL
Intervention: Structured lifestyle self-management education sessions (four 2.5-hour sessions, 1 week apart; multimodal fortnightly support contacts; three 2.5-hour booster sessions at 3-month intervals)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Structured lifestyle self-management education sessions
Number of subjects: 414

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 414
Study: 26742066

Group type: EXPERIMENTAL
Intervention: Low glycaemic index dietary advice during pregnancy
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control group (standard dietary advice)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Maternal dietary intake (trimester three GI, trimester two saturated fats, trimester one and three sodium)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Maternal dietary intake (trimester two and three vitamin C)
Number of subjects: 280
Study: 24217934

Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg/day
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 24406355

Group type: EXPERIMENTAL
Intervention: High crossectomy without vascular sectioning (HCWVS)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Classic saphenectomy (CS)
Number of subjects: 150
Study: 20723187

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation (100,000 iu) along with antibiotics
Number of subjects: 453

Group type: COMPARATOR
Intervention: Placebo along with antibiotics
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) supplementation
Number of subjects: 453

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 453
Study: 18406037

Group type: EXPERIMENTAL
Intervention: ACLS skills
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: BLS skills
Number of subjects: 133
Study: 16005520

Group type: EXPERIMENTAL
Intervention: QI-Therapy
Number of subjects: 1356

Group type: EXPERIMENTAL
Intervention: QI-Meds
Number of subjects: 1356

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 1356
Study: 14629655

Group type: EXPERIMENTAL
Intervention: Delipidated acid-treated M. vaccae (0.4 mg first dose, 0.8 mg second dose)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Phosphate buffered saline (placebo)
Number of subjects: 37
Study: 10585042

Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia (group 1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Antegrade/retrograde cardioplegia (group 2)
Number of subjects: 75
Study: 8760546

Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen therapy (HBO) - 100% O2 at 2.5 ata for 90 minutes, twice daily, over 6 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo - 21% O2 at 1.1 ata for 90 minutes, twice daily, over 6 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen therapy (HBO)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 1750819

Group type: EXPERIMENTAL
Intervention: Treatment (exact intervention not specified)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 74
Study: 6217022

Group type: EXPERIMENTAL
Intervention: Sodium lauryl sulfate (SLS) applied in concentrations ranging from 0.001% to 5% under occlusion for 24 hours.
Number of subjects: 950

Group type: COMPARATOR
Intervention: Visual scoring of skin irritancy reactions.
Number of subjects: 950
Study: 31271608

Group type: COMPARATOR
Intervention: Standard urotherapy
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Standard urotherapy associated with pelvic floor muscle training
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Standard urotherapy associated with pelvic floor muscle training and oxybutynin
Number of subjects: 38
Study: 29098247

Group type: EXPERIMENTAL
Intervention: Er:YAG laser as an adjunctive to scaling and root planning (SRP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (SRP only)
Number of subjects: 11
Study: 27158853

Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 465
Study: 25156568

Group type: EXPERIMENTAL
Intervention: High OC group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low OC group
Number of subjects: 0

Group type: COMPARATOR
Intervention: High trait anxiety group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low trait anxiety group
Number of subjects: 0
Study: 21911313

Group type: EXPERIMENTAL
Intervention: Cryotherapy (holding ice cubes in mouth before, during, and after chemotherapy)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (routine care)
Number of subjects: 60
Study: 19434929

Group type: EXPERIMENTAL
Intervention: High-dose IFN‐α‐2b induction therapy combined with amantadine and ribavirin for 6 weeks followed by weekly pegylated IFN‐α‐2b for 24 or 48 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-dose IFN‐α‐2b induction therapy
Number of subjects: 31
Study: 17103193

Group type: EXPERIMENTAL
Intervention: 2 g-IVIG
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 1 g-IVIG
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: 1 g-IVIG with additional IVIG
Number of subjects: 109
Study: 15319712

Group type: COMPARATOR
Intervention: Heller myotomy
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Heller myotomy plus Dor fundoplication
Number of subjects: 43
Study: 11429399

Group type: EXPERIMENTAL
Intervention: Amiodarone (1.5, 3, 5, 7, and 10 microM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desethylamiodarone (primary metabolite of amiodarone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amiodarone (oral administration for 4 weeks)
Number of subjects: 0
Study: 9599521

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (two inhalations of 1000 micrograms)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intramuscular dexamethasone (0.6 mg/kg)
Number of subjects: 59
Study: 8020641

Group type: EXPERIMENTAL
Intervention: Postprandial hypotension intervention
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (water only)
Number of subjects: 15
Study: 2744928

Group type: EXPERIMENTAL
Intervention: Exercise at 40% of maximal workload with carbohydrate feeding (25% maltodextrin-fructose solution) for 2.5 hours
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rest for 2.5 hours with carbohydrate feeding (25% maltodextrin-fructose solution)
Number of subjects: 16
Study: 1253811

Group type: EXPERIMENTAL
Intervention: Aldosterone infusion before fasting and on day 4 of fasting
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Spironolactone treatment (300 mg/day p.o.) on days 6 to 8 of the fast
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Glucose load (100 g) on day 7
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Salivary sodium output measurement
Number of subjects: 32
Study: 31770449

Group type: EXPERIMENTAL
Intervention: Surgeons' prediction scores based on injury and initial postoperative radiographs
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Surgeons' prediction confidence level greater than 1 SD above the mean
Number of subjects: 95

Group type: COMPARATOR
Intervention: Surgeons' prediction ability
Number of subjects: 95

Group type: COMPARATOR
Intervention: Characteristics associated with lower prediction scores
Number of subjects: 95
Study: 30648318

Group type: EXPERIMENTAL
Intervention: Active radiofrequency exposure
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sham exposure
Number of subjects: 18
Study: 28291296

Group type: EXPERIMENTAL
Intervention: Feedback condition
Number of subjects: 84

Group type: COMPARATOR
Intervention: No feedback condition
Number of subjects: 84
Study: 24460000

Group type: EXPERIMENTAL
Intervention: 4-hour on-the-job classroom training (Team Awareness Program and Choices in Health Promotion Program)
Number of subjects: 1510

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 1510
Study: 24482945

Group type: EXPERIMENTAL
Intervention: Intramuscular ACTH stimulation test using Acton Prolongatum (25 units injected intramuscularly)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Basal cortisol measurement
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Post ACTH serum cortisol
Number of subjects: 150

Group type: COMPARATOR
Intervention: Basal and post ACTH serum cortisol levels in healthy adults and patients with diabetes mellitus and primary hypothyroidism
Number of subjects: 150

Group type: COMPARATOR
Intervention: Comparison of basal cortisol levels between patients with known adrenal insufficiency and controls
Number of subjects: 150
Study: 20820169

Group type: EXPERIMENTAL
Intervention: Obese virtual patient
Number of subjects: 76

Group type: COMPARATOR
Intervention: Non-obese virtual patient
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Clinical recommendations
Number of subjects: 76
Study: 18556361

Group type: EXPERIMENTAL
Intervention: Medulla oblongata volume (MOV) in patients with MS
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 45
Study: 15910892

Group type: EXPERIMENTAL
Intervention: Ajulemic acid (AJA) 40 mg and 80 mg daily
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ajulemic acid (AJA)
Number of subjects: 21
Study: 14522763

Group type: EXPERIMENTAL
Intervention: Oral acyclovir 400 mg twice daily for 6 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo tablets for 6 months
Number of subjects: 68
Study: 10945510

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl 600 mg/d
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 8803646

Group type: EXPERIMENTAL
Intervention: D-amphetamine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: L-fenfluramine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: D-fenfluramine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: D-amphetamine + D-fenfluramine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: D-amphetamine + L-fenfluramine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1611459

Group type: EXPERIMENTAL
Intervention: Biofragmentable anastomotic ring (Valtrac‐BAR)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Hand-suture with a two-layer anastomosis of resorbable suture material (3/0 Dexon)
Number of subjects: 150
Study: 6418300

Group type: EXPERIMENTAL
Intervention: Real electroconvulsive therapy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Simulated electroconvulsive therapy
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy
Number of subjects: 138
Study: 31389835

Group type: EXPERIMENTAL
Intervention: McGrath Mac Video Laryngoscope
Number of subjects: 514

Group type: COMPARATOR
Intervention: Direct Laryngoscopy
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Switching device after failed first attempt
Number of subjects: 514
Study: 29127547

Group type: EXPERIMENTAL
Intervention: Magnesium and zinc co-supplementation (250 mg of magnesium oxide plus 220 mg of zinc sulfate containing 50 mg zinc)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 26649759

Group type: COMPARATOR
Intervention: Familiar language (English)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unfamiliar language (Spanish or Icelandic)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Both familiar and unfamiliar languages
Number of subjects: 0
Study: 24949908

Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy (ICBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive behavioral group therapy (CBGT)
Number of subjects: 0
Study: 22498745

Group type: EXPERIMENTAL
Intervention: Bortezomib-thalidomide-dexamethasone (VTD)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Thalidomide-dexamethasone (TD)
Number of subjects: 236
Study: 20440639

Group type: EXPERIMENTAL
Intervention: Nonintensive parent training plus care-as-usual
Number of subjects: 75

Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 75
Study: 30336805

Group type: EXPERIMENTAL
Intervention: ZX008 0.8 mg/kg
Number of subjects: 26

Group type: COMPARATOR
Intervention: STP regimen (stiripentol 3,500 mg, clobazam 20 mg, valproate 25 mg/kg, max. 1,500 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: ZX008 0.8 mg/kg + STP regimen
Number of subjects: 26
Study: 14614647

Group type: EXPERIMENTAL
Intervention: Metformin, thiazolidinediones, and acarbose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of metformin and thiazolidinediones with sulphonylureas or meglitinides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nateglinide and repaglinide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 0
Study: 10702176

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200000 IU)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study: 9099461

Group type: EXPERIMENTAL
Intervention: High-dose adjuvant CAF chemotherapy
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: Standard-dose adjuvant CAF chemotherapy
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: Low-dose adjuvant CAF chemotherapy
Number of subjects: 1572
Study: 8402326

Group type: EXPERIMENTAL
Intervention: Vitamin K (1 mg/day) for 2 weeks
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Vitamin K (1 mg/day) for 3 months
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo treatment for 3 months
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Vitamin K (1 mg/day) for 3 months in fast losers of urinary calcium
Number of subjects: 285
Study: 3081221

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily for six weeks)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 604
Study: 31665942

Group type: EXPERIMENTAL
Intervention: Neuronox® (24 U)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Onabotulinumtoxin A (ONA) (24 U)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Neuronox® and ONA
Number of subjects: 250
Study: 30129434

Group type: EXPERIMENTAL
Intervention: Supportive living healthcare aides
Number of subjects: 23

Group type: COMPARATOR
Intervention: LTC residents
Number of subjects: 23
Study: 27183454

Group type: EXPERIMENTAL
Intervention: Training general practitioners (GPS) in optimizing HF medication
Number of subjects: 92

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 92
Study: 23896197

Group type: EXPERIMENTAL
Intervention: Stretching group (10 s for 9 repetitions)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Stretching group (30 s for 3 repetitions)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 22130108

Group type: EXPERIMENTAL
Intervention: BRIDGES intervention
Number of subjects: 428

Group type: COMPARATOR
Intervention: Control (services as usual wait list)
Number of subjects: 428
Study: 20658830

Group type: EXPERIMENTAL
Intervention: Intensive intervention ('adherence improving') for patients with <95% adherence
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group received high-quality usual care
Number of subjects: 133
Study: 18544642

Group type: EXPERIMENTAL
Intervention: Pioglitazone treatment for 10 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Palmitate, tunicamycin, and thapsigargin (in vitro)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pioglitazone pretreatment (in vitro)
Number of subjects: 20
Study: 16447591

Group type: EXPERIMENTAL
Intervention: Periprostatic plexus anesthesia (PPA) with 10 cc lidocaine, 2% diluted 50%
Number of subjects: 275

Group type: COMPARATOR
Intervention: No anesthesia (control group)
Number of subjects: 275
Study: 12742468

Group type: EXPERIMENTAL
Intervention: sirolimus
Number of subjects: 83

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 83
Study: 10569556

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg twice daily for 3 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 25
Study: 8791132

Group type: EXPERIMENTAL
Intervention: Aspirin and NSAIDs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet high in vegetables and natural fibers, low in fat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular physical exercise and maintenance of normal body weight
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food fortification or supplementation
Number of subjects: 0
Study: 1989710

Group type: EXPERIMENTAL
Intervention: Cytobrush
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Spatula
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Swab
Number of subjects: 136